PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 4493: Comprehensive assay approaches for PRMT5 targeted drug discovery.

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJianghong WuCSCharles SchmidtJSJamin D. Steffen

Discussion

Loading...

Member takes

Overview

This research demonstrates potent inhibition of PRMT5 in cancer using targeted drug discovery assays, implying new therapeutic options.

Key Points

  • The aim is to develop and validate assay platforms for identifying and characterizing PRMT5 inhibitors for cancer treatment.
  • Established biochemical FlashPlate and NanoBRET assays for PRMT5 activity and inhibitor engagement
  • Biochemical assays measured IC50 for known inhibitors in the low nanomolar range
  • Utilized Surface Plasmon Resonance to analyze binding profiles of inhibitors with and without cofactors
  • Performed Western blot analysis on cancer cell lines to confirm inhibition of specific methylation marks
  • Inhibitors demonstrated potent inhibition of PRMT5/MEP50 activity with IC50 values ranging from 0.6 to 17 nM
  • Distinct binding profiles observed for substrate-competitive and cofactor-competitive inhibitors
  • PRMT5 inhibitors engaged the PRMT5/MEP50 complex within one hour in live HEK293 cells
  • Inhibition of histone H4R3me2s methylation was confirmed in several cancer cell lines

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcd4a79560c99a0a28b6https://doi.org/10.1158/1538-7445.am2026-4493
View Full Paper
Ask AI
Bookmark
Share